When von Willebrand disease comes into age - a matter of change?

European Journal of Haematology

Volumn 86, Issue 6, 2011, Pages 496-501

  Miesbach, Wolfgang ^a   Berntorp, Erik ^b  

^a GOETHE UNIVERSITY   (Germany)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Age; Von Willebrand disease; Von Willebrand factor

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; DESMOPRESSIN; DIURETIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; RECOMBINANT BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR;

AGING; ARTICLE; ATHEROSCLEROSIS; BLEEDING; COMORBIDITY; DEEP VEIN THROMBOSIS; EPISTAXIS; EVIDENCE BASED PRACTICE; GASTROINTESTINAL HEMORRHAGE; HEMARTHROSIS; HEMOPHILIA; HUMAN; HYPONATREMIA; MENORRHAGIA; ORAL BLEEDING; POSTPARTUM HEMORRHAGE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOEMBOLISM; VASOCONSTRICTION; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; VON WILLEBRAND DISEASE;

AGED; AGING; DEAMINO ARGININE VASOPRESSIN; FACTOR VIII; HEMOSTASIS; HUMANS; THROMBOEMBOLISM; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR; WATERHOUSE-FRIDERICHSEN SYNDROME;

EID: 79955999740     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2011.01611.x     Document Type: Article

References (34)

1. de Wee EM, Mauser-Bunschoten EP, Van Der Bom JG, et al. Health-related quality of life among adult patients with moderate and severe von Willebrand disease. J Thromb Haemost 2010;8:1492-9.
2. Sagripanti A, Carpi A. Natural anticoagulants, aging, and thromboembolism. Exp Gerontol 1998;33:891-6.
3. Mari D, Coppola R, Provenzano R. Hemostasis factors and aging. Exp Gerontol 2008;43:66-73.
4. Whincup PH, Danesh J, Walker M, Lennon L, Thomson A, Appleby P, Rumley A, Lowe GD. von Willebrand factor and coronary heart disease: prospective study and meta-analysis. Eur Heart J 2002;23:1764-70.
5. Coppola R, Mari D, Lattuada A, Franceschi C. Von Willebrand factor in Italian centenarians. Haematologica 2003;88:39-43.
6. Aillaud MF, Pignol F, Alessi MC, Harle JR, Escande M, Mongin M, Juhan-Vague I. Increase in plasma concentration of plasminogen activator inhibitor, fibrinogen, von Willebrand factor, factor VIII:C and in erythrocyte sedimentation rate with age. Thromb Haemost 1986;55:330-2.
7. Conlan MG, Folsom AR, Finch A, Davis CE, Sorlie P, Marcucci G, Wu KK. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost 1993;70:380-5.
8. Tracy RP, Bovill EG, Fried LP, Heiss G, Lee MH, Polak JF, Psaty BM, Savage PJ. The distribution of coagulation factors VII and VIII and fibrinogen in adults over 65 years. Results from the Cardiovascular Health Study. Ann Epidemiol 1992;2:509-19.
9. Miesbach W, Alesci W, Krekeler S, Seifried E. Age-dependent increase of FVIII:C in mild haemophilia A. Haemophilia 2009;15:1022-6.
10. Lowe GD, Rumley A, Woodward M, Morrison CE, Philippou H, Lane DA, Tunstall-Pedoe H. Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey. I. Illustrative reference ranges by age, sex and hormone use. Br J Haematol 1997;97:775-84.
11. Miesbach W, Alesci S, Krekeler S, Seifried E. Co-morbidities and bleeding pattern in elderly haemophilia A patients. Haemophilia 2009;15:894-9.
12. Tosetto A, Castaman G, Rodeghiero F. Assessing bleeding in von Willebrand disease with bleeding score. Blood Rev 2007;21:89-97.
13. Berntorp E, Windyga J; European Wilate Study Group. Treatment and prevention of acute bleedings in von Willebrand disease - efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate. Haemophilia 2009;15:122-30.
14. Goodeve AC, James P. von Willebrand disease. In: Pagon RA, Bird TC, Dolan CR, Stephens K, eds. GeneReviews [Internet]. Seattle, WA: University of Washington; 2009:1993.
15. Berntorp E, Abshire T; von Willebrand Disease Prophylaxis Network Steering Committee. The von Willebrand disease prophylaxis network: exploring a treatment concept. J Thromb Haemost 2006;4:2511-2.
16. Federici AB, Mannucci PM. Management of inherited von Willebrand disease in 2007. Ann Med 2007;39:356-8.
17. Sadler JE, Budde U, Eikenbgoom JC, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand factor. J Thromb Haemost 2006;4:2103-14.
18. Federici AB, Castaman G, Mannucci PM; The Italian Association of Hemophilia Centers (AICE). Guidelines for the diagnosis and management of von Willebrand disease in Italy. Haemophilia 2002;8:607-21.
19. Federici AB. Update on the management of von Willebrand disease. Clin Adv Hematol Oncol 2008;6:29-30.
20. Borel-Derlon A, Federici AB, Roussel-Robert V, et al. Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients. J Thromb Haemost 2007;5:1115-24.
21. Mannucci PM. Venous thromboembolism in von Willebrand disease. Thromb Haemost 2002;88:378-9.
22. Lethagen S, Kyrle PA, Castaman G, Haertel S, Mannucci PM; HAEMATE P Surgical Study Group. von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery. J Thromb Haemost 2007;5:1420-30.
23. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995;332:635-41.
24. Wieberdink RG, van Schie MC, Koudstaal PJ, Hofman A, Witteman JC, de Maat MP, Leebeek FW, Breteler MM. High von Willebrand factor levels increase the risk of stroke: the Rotterdam study. Stroke 2010;41:2151-6.
25. Catto AJ, Carter AM, Barrett JH, Barnford J, Rice PJ, Grant PJ. Von Willebrand factor and factor VIII/C in acute cerebrovascular disease. Thromb Haemost 1997;77:1104-8.
26. Sramek A, Bucciarelli P, Federici AB, et al. Patients with type 3 severe von Willebrand disease are not protected against atherosclerosis. Results from a multicenter study in 47 patients. Circulation 2004;109:740-4.
27. Bilora F, Zanon E, Casonato A, et al. Type IIB von Willebrand disease: role of qualitative defects in atherosclerosis and endothelial dysfunction. Clin Appl Thromb Hemost 2007;13:384-90.
28. Rosendaal FR, Varekamp I, Smit C, Bröcker-Vriends AH, van Dijck H, Vandenbroucke JP, Hermans J, Suurmeijer TP, Briët E. Mortality and causes of death in Dutch haemophiliacs, 1973-86. Br J Haematol 1989;71:71-6.
29. Rosendaal FR, Briët E, Stibbe J, van Herpen G, Leuven JA, Hofman A, Vandenbroucke JP. Haemophilia protects against ischaemic heart disease: a study of risk factors. Br J Haematol 1990;75:525-30.
30. Srámek A, Kriek M, Rosendaal FR. Decreased mortality of ischaemic heart disease among carriers of haemophilia. Lancet 2003;362:351-4.
31. Darby SC, Kan SW, Spooner RJ, Giangrande PLF, Hill FGH, Hay CRM, Lee CA, Ludlam CA, Williams M; The UK Haemophilia Centre Doctors' Organisation. Mortality rates, life expectancy, and causes of death in people with haemophilia A or B in the United Kingdom who were not infected with HIV. Blood 2007;110:815-25.
32. Kulkarni R, Soucie JM, Evatt BL; Hemophilia Surveillance System Project Investigators. Prevalence and risk factors for heart disease among males with hemophilia. Am J Hematol 2005;79:36-42.
33. Federici AB. The safety of plasma-derived von Willebrand/factor VIII concentrates in the management of inherited von Willebrand disease. Expert Opin Drug Saf 2009;8:203-10.
34. Goudemand J, Negrier C, Ounnoughene N, Sultan Y. Clinical management of patients with von Willebrand disease with a VHP VWF concentrate: the France experience. Haemophilia 1998;4(Suppl. 3):48-52.